BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 29396568)

  • 21. Does ligand-receptor mediated competitive effect or penetrating effect of iRGD peptide when co-administration with iRGD-modified SSL?
    Zhang WQ; Yu KF; Zhong T; Luo LM; Du R; Ren W; Huang D; Song P; Li D; Zhao Y; Wang C; Zhang X
    J Drug Target; 2015 Dec; 23(10):897-909. PubMed ID: 26087869
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A modified thymosin alpha 1 inhibits the growth of breast cancer both in vitro and in vivo: suppressment of cell proliferation, inducible cell apoptosis and enhancement of targeted anticancer effects.
    Lao X; Li B; Liu M; Shen C; Yu T; Gao X; Zheng H
    Apoptosis; 2015 Oct; 20(10):1307-20. PubMed ID: 26283169
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enhancing Accumulation and Penetration of HPMA Copolymer-Doxorubicin Conjugates in 2D and 3D Prostate Cancer Cells via iRGD Conjugation with an MMP-2 Cleavable Spacer.
    Peng ZH; Kopeček J
    J Am Chem Soc; 2015 Jun; 137(21):6726-9. PubMed ID: 25963409
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Novel Strategy to Improve the Therapeutic Efficacy of Gemcitabine for Non-Small Cell Lung Cancer by the Tumor-Penetrating Peptide iRGD.
    Zhang Q; Zhang Y; Li K; Wang H; Li H; Zheng J
    PLoS One; 2015; 10(6):e0129865. PubMed ID: 26066322
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapeutic Peptide Amphiphile as a Drug Carrier with ATP-Triggered Release for Synergistic Effect, Improved Therapeutic Index, and Penetration of 3D Cancer Cell Spheroids.
    Lu S; Zhao F; Zhang Q; Chen P
    Int J Mol Sci; 2018 Sep; 19(9):. PubMed ID: 30223518
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The antitumor activity of a doxorubicin loaded, iRGD-modified sterically-stabilized liposome on B16-F10 melanoma cells: in vitro and in vivo evaluation.
    Yu KF; Zhang WQ; Luo LM; Song P; Li D; Du R; Ren W; Huang D; Lu WL; Zhang X; Zhang Q
    Int J Nanomedicine; 2013; 8():2473-85. PubMed ID: 23885174
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumor-penetrating peptide fused to a pro-apoptotic peptide facilitates effective gastric cancer therapy.
    Huang Y; Li X; Sha H; Zhang L; Bian X; Han X; Liu B
    Oncol Rep; 2017 Apr; 37(4):2063-2070. PubMed ID: 28260064
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enhanced Penetrability of a Tetrahedral Framework Nucleic Acid by Modification with iRGD for DOX-Targeted Delivery to Triple-Negative Breast Cancer.
    Liu M; Ma W; Zhao D; Li J; Li Q; Liu Y; Hao L; Lin Y
    ACS Appl Mater Interfaces; 2021 Jun; 13(22):25825-25835. PubMed ID: 34038071
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-EGFR-iRGD recombinant protein modified biomimetic nanoparticles loaded with gambogic acid to enhance targeting and antitumor ability in colorectal cancer treatment.
    Zhang Z; Qian H; Huang J; Sha H; Zhang H; Yu L; Liu B; Hua D; Qian X
    Int J Nanomedicine; 2018; 13():4961-4975. PubMed ID: 30214200
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor-penetration and antitumor efficacy of cetuximab are enhanced by co-administered iRGD in a murine model of human NSCLC.
    Zhang Y; Yang J; Ding M; Li L; Lu Z; Zhang Q; Zheng J
    Oncol Lett; 2016 Nov; 12(5):3241-3249. PubMed ID: 27899989
    [TBL] [Abstract][Full Text] [Related]  

  • 31. iRGD Co-Administration with Paclitaxel-Loaded PLGA Nanoparticles Enhance Targeting and Antitumor Effect in Colorectal Cancer Treatment.
    Li L; Yang M; Li R; Hu J; Yu L; Qian X
    Anticancer Agents Med Chem; 2021; 21(7):910-918. PubMed ID: 32698755
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bifunctional iRGD-anti-CD3 enhances antitumor potency of T cells by facilitating tumor infiltration and T-cell activation.
    Zhou S; Meng F; Du S; Qian H; Ding N; Sha H; Zhu M; Yu X; Wang L; Liu B; Wei J
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33986122
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cellular Internalization and Inhibition Capacity of New Anti-Glioma Peptide Conjugates: Physicochemical Characterization and Evaluation on Various Monolayer- and 3D-Spheroid-Based
    Baranyai Z; Biri-Kovács B; Krátký M; Szeder B; Debreczeni ML; Budai J; Kovács B; Horváth L; Pári E; Németh Z; Cervenak L; Zsila F; Méhes E; Kiss É; Vinšová J; Bősze S
    J Med Chem; 2021 Mar; 64(6):2982-3005. PubMed ID: 33719423
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A tumor-penetrating peptide enhances circulation-independent targeting of peritoneal carcinomatosis.
    Sugahara KN; Scodeller P; Braun GB; de Mendoza TH; Yamazaki CM; Kluger MD; Kitayama J; Alvarez E; Howell SB; Teesalu T; Ruoslahti E; Lowy AM
    J Control Release; 2015 Aug; 212():59-69. PubMed ID: 26071630
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Increased antitumor activity of tumor-specific peptide modified thymopentin.
    Lao X; Li B; Liu M; Chen J; Gao X; Zheng H
    Biochimie; 2014 Dec; 107 Pt B():277-85. PubMed ID: 25236717
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pulmonary delivery of transferrin receptors targeting peptide surface-functionalized liposomes augments the chemotherapeutic effect of quercetin in lung cancer therapy.
    Riaz MK; Zhang X; Wong KH; Chen H; Liu Q; Chen X; Zhang G; Lu A; Yang Z
    Int J Nanomedicine; 2019; 14():2879-2902. PubMed ID: 31118613
    [No Abstract]   [Full Text] [Related]  

  • 37. Anticancer effects of gemcitabine are enhanced by co-administered iRGD peptide in murine pancreatic cancer models that overexpressed neuropilin-1.
    Akashi Y; Oda T; Ohara Y; Miyamoto R; Kurokawa T; Hashimoto S; Enomoto T; Yamada K; Satake M; Ohkohchi N
    Br J Cancer; 2014 Mar; 110(6):1481-7. PubMed ID: 24556620
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preparation and Characterization of Dentin Phosphophoryn-Derived Peptide-Functionalized Lignin Nanoparticles for Enhanced Cellular Uptake.
    Figueiredo P; Sipponen MH; Lintinen K; Correia A; Kiriazis A; Yli-Kauhaluoma J; Österberg M; George A; Hirvonen J; Kostiainen MA; Santos HA
    Small; 2019 Jun; 15(24):e1901427. PubMed ID: 31062448
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tumor-penetrating iRGD peptide inhibits metastasis.
    Sugahara KN; Braun GB; de Mendoza TH; Kotamraju VR; French RP; Lowy AM; Teesalu T; Ruoslahti E
    Mol Cancer Ther; 2015 Jan; 14(1):120-8. PubMed ID: 25392370
    [TBL] [Abstract][Full Text] [Related]  

  • 40. sTRAIL-iRGD is a promising therapeutic agent for gastric cancer treatment.
    Huang Y; Li X; Sha H; Zhang L; Bian X; Han X; Liu B
    Sci Rep; 2017 Apr; 7(1):579. PubMed ID: 28373646
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.